Phase 3CompletedAge-related condition

A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause (Skylight 4)

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Sponsor
Astellas Pharma Global Development, Inc. (Industry)
Enrollment
1,831 enrolled
Conditions
Hot Flashes
Interventions
fezolinetant; placebo
Ages
adults, older adults
Registry
NCT04003389, EUCTR2019-000275-16

Full record on ClinicalTrials.gov

From the registry

This study was for women in menopause with hot flashes. Menopause, a normal part of aging, was the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The purpose of this study was to find out how safe it is for these women to take fezolinetant in long term (up to 52 weeks). To do that, the study looked at the number and severity of the "adverse events." Those were the side effects that study participants had while they were in the study. The study treatments were fezolinetant 30 milligrams (mg) (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo was a dummy treatment that looked like medicine but did not have any medicine in it.) Women in this study were picked for 1 of the 3 study treatments by chance alone. The study participants took study treatment for 52 weeks. This study was "double-blinded." That means that the study participants and the study doctors did not know who took which of the study treatments (fezolinetant 30 mg, fezolinetant…

Primary outcomes

  • Number of Participants With Treatment Emergent Adverse Events (TEAEs)
  • Number of Participants With Mild, Moderate and Severe TEAE
  • Percentage of Participants With Endometrial Hyperplasia
  • Percentage of Participants With Endometrial Cancer

History

  1. Last registry update

  2. Results first posted

  3. Primary completion

  4. Started

  5. Registered

Papers citing this trial